mRNA Drug Substance
Linearization, in-vitro transcription, co-transcriptional and enzymatic capping, tailing, and orthogonal purification — at research, clinical, and commercial scale.
mRNA Services CDMO
Engineering the next generation of mRNA medicines
Diabryx is your end-to-end partner for mRNA drug substance and lipid nanoparticle drug product — uniting process development, GMP manufacturing, and analytics under one integrated network, from preclinical concept to commercial supply.
IVT drug substance
LNP encapsulation
saRNA & circRNA
cGMP commercial
One integrated platform
From sequence to sterile vial, under one roof
Our vertically integrated capability set removes the hand-offs that slow mRNA programs down. Synthesis, formulation, fill-finish, and analytics share data, materials, and quality systems across a single network.
LNP Drug Product
Our proprietary FluxMix™ microfluidic encapsulation platform delivers tight, reproducible lipid nanoparticles, formulated buffer exchange, and aseptic fill-finish.
Analytical Development
Phase-appropriate methods for identity, integrity, capping efficiency, encapsulation, particle size, and potency — purpose-built for RNA and LNP modalities.
Process Development
Design-of-experiments optimization, scale-down models, and a manufacturing-ready process designed for transfer from day one.
Tech Transfer
Bring your established process, or co-develop with us. Either way, a dedicated transfer team mirrors your methods and de-risks every scale-up milestone.
Dedicated Capacity
Reserve suites, lines, and teams for your portfolio. Predictable slots, agile ramp-up, and supply security through every phase of your pipeline.
18+
Years of cGMP experience
140k
Sq ft of dedicated mRNA space
3
Integrated facilities, 2 continents
60+
Programs supported to date
What we do
Services that flex to your program — not the other way around
Drug substance, made manufacturing-ready
From a sequence and a plasmid, we build a robust IVT process tuned for yield, integrity, and capping efficiency — then carry it cleanly into GMP. Single-use, closed-system workflows keep changeovers fast and cross-contamination risk low.
- Plasmid linearization and template QC
- High-yield in-vitro transcription with modified nucleosides
- Co-transcriptional capping and defined poly(A) tailing
- Orthogonal, scalable purification trains
LNP formulation, reproducible at any scale
Our FluxMix™ microfluidic mixing platform encapsulates RNA into uniform lipid nanoparticles with a consistency that survives scale-up. Controlled mixing geometry, in-line process analytics, and aseptic fill-finish carry your drug product from bench to clinic to market.
- Microfluidic encapsulation with tight PDI control
- Tangential-flow buffer exchange and concentration
- Sterile filtration and aseptic fill-finish
- Lipid sourcing, qualification, and custom formulation
The Diabryx journey
One partner across the full lifecycle
No re-bidding, no re-validating with a new vendor at each phase. We stay with your molecule from first transcription to commercial release.
01
Design & Preclinical
Construct design, research-grade material, and in-vivo-ready LNP formulations to power your discovery work.
02
Process Development
DoE-driven optimization and scale-down models that lock in a robust, transferable process.
03
Clinical GMP
Phase-appropriate cGMP drug substance and drug product to support your first-in-human programs.
04
Commercial Supply
Validated commercial manufacturing, dedicated capacity, and resilient, audited global supply.
Ready to accelerate your mRNA program?
Tell us where your molecule is today. We'll map the fastest, lowest-risk path to your next milestone — and stay with you all the way to commercial.